Arbutus Biopharma (ABUS) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

$ABUS Stock Is up 7% Today. Here's What We See in Our Data.
Quiver QuantitativeFeb 25 10:30 ET
Arbutus Biopharma's Entire Board Replaced as New CEO Steps In
WSJFeb 25 07:47 ET
Express News | Arbutus Biopharma Corp - to Pause Investor Meetings During Strategic Review
ReutersFeb 25 07:01 ET
Express News | Arbutus Biopharma Corp - All Existing Arbutus Board Members Step Down
ReutersFeb 25 07:01 ET
Press Release: Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Dow JonesFeb 25 07:00 ET
Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO
Arbutus BiopharmaFeb 25 00:00 ET

Comments

Jaguar8

Nov 15, 2024 10:05

ADDED NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus Biopharma (ABUS) announced promising results from its IM-PROVE I Phase 2a clinical trial for imdusiran, its RNAi therapeutic for chronic hepatitis B virus (cHBV).
When combined with 24 weeks of pegylated interferon and nucleos(t)ide analogue therapy, the treatment achieved a 50% functional cure rate (3/6 patients) in patients with baseline ...

1

Jaguar8

Nov 15, 2024 10:02

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial for chronic hepatitis B treatment.
The study evaluated the combination of imdusiran, VTP-300, and low-dose nivolumab.
Key findings show that 23% of participants receiving the triple combinati...

1

Jaguar8

Oct 15, 2024 07:58

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
Key findings fr...

Trytosaveabit

Aug 1, 2024 06:56

Update

$Arbutus Biopharma (ABUS.US)$ Trading quotes resume at 7:55 and trading at 8:00AM est

2

Trytosaveabit

Aug 1, 2024 06:32

News

$Arbutus Biopharma (ABUS.US)$ Reuters· 1 min ago
Arbutus Biopharma Corp: Prioritizing Imdusiran Phase 2B Clinical Development. Also planning 40% reduction in workforce

1

ABUS Arbutus Biopharma

Trade Overview

Capital Trend

News

Comments

Trending Stocks